Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365525 | 1.00 | KLK7 (0.47) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL2580045 | 0.97 | KLK7 (0.50) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL2566766 | 0.91 | SIRT2 (0.48) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL29387849 | 0.90 | KLK7 (0.54) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL9933450 | 0.89 | KLK7 (0.53) | KLK7KLK5TLR2TLR1MAPT | |
| SCHEMBL18568079 | 0.89 | KLK7 (0.53) | KLK7KLK5TLR2TLR1MAPT | |
| SCHEMBL10242708 | 0.89 | KLK7 (0.54) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL12127581 | 0.87 | KLK7 (0.47) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL6200922 | 0.87 | KLK7 (0.52) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL30266828 | 0.87 | KLK7 (0.51) | KLK7KLK5TLR2TLR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349241-B1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9534014-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| US-9040032-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040032-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2015-01-29 | — | — | US | disclosed |
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2015-01-29 | — | — | US | disclosed |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2011-11-17 | — | — | US | disclosed |
| WO-2011133178-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED TAPENTADOL PRODRUG | PHARMACOFORE, INC (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133178-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED TAPENTADOL PRODRUG | PHARMACOFORE, INC (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| EP-2349241-A1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | Pharmacofore, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010045599-A1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | PHARMACOFORE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | KLK7 1349/4885KLK5 972/4885SIRT2 4301/4885 |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | COMT, OPRM1, DNPEP | KLK7 1134/4885KLK5 974/4885SIRT2 3921/4885 |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PEPD, TMPRSS15, ADAM17 | KLK7 895/4885KLK5 832/4885SIRT2 2650/4885 |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | ACHE, OPRM1, DNPEP | KLK7 801/4885KLK5 831/4885SIRT2 4482/4885 |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | KLK7 1349/4885KLK5 972/4885SIRT2 4301/4885 |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | KLK7 801/4885KLK5 831/4885SIRT2 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.